7Steinshamn S, Sandsund M, Sue-Chu M, et al. Effects of montelukast on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction[J]. Scand J Med Sci Sports , 2002, 12(4):211-217.
8Niewoehner DE. Montelukast improved pulmonary function and asthma-specific quality of life in aspirin-intolerant asthma[J]. ACP J Club, 2002, 137(1):20.
9Zhang J, Yu C, Noonan G, et al. Effect of montelukast, a once-daily leukotriene receptor antagonist, on peak expiratory flow variability[J]. Clin Ther, 2002, 24(4):574-582.
10Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresportsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor ( sIL-2R), IL-4, and soluble intercellular adhesion molecule 1(sICAM-1) in children with asthma[J]. J Allergy Clin Immunol, 2002, 109(2) :257 - 263.
6Knorr B;Mata J;Bermstein J.Montelukast for chronic asthma in 6-14 years,a randomized,double-blind trial[J],1998(15).
7Edelman JM;Turpin JA;Bronsky EA.Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction,2000(02).
8Barnes NC;Smith LJ.Biochemistry and physiology of the leukotrienes[J],1999(1-2).
9Holgate ST.Leukotriene receptor antagonist,montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients,2003(02).
10Bisgaard H.Leukotriene modifiers in pediatric asthma management[J],2001(02).
